BCL‐XL exerts a protective role against anemia caused by radiation‐induced kidney damage
- 25 November 2020
- journal article
- research article
- Published by EMBO in The EMBO Journal
- Vol. 39 (24), e105561
- https://doi.org/10.15252/embj.2020105561
Abstract
Studies of gene‐targeted mice identified the roles of the different pro‐survival BCL‐2 proteins during embryogenesis. However, little is known about the role(s) of these proteins in adults in response to cytotoxic stresses, such as treatment with anti‐cancer agents. We investigated the role of BCL‐XL in adult mice using a strategy where prior bone marrow transplantation allowed for loss of BCL‐XL exclusively in non‐hematopoietic tissues to prevent anemia caused by BCL‐XL deficiency in erythroid cells. Unexpectedly, the combination of total body γ‐irradiation (TBI) and genetic loss of Bcl‐x caused secondary anemia resulting from chronic renal failure due to apoptosis of renal tubular epithelium with secondary obstructive nephropathy. These findings identify a critical protective role of BCL‐XL in the adult kidney and inform on the use of BCL‐XL inhibitors in combination with DNA damage‐inducing drugs for cancer therapy. Encouragingly, the combination of DNA damage‐inducing anti‐cancer therapy plus a BCL‐XL inhibitor could be tolerated in mice, at least when applied sequentially.Keywords
Funding Information
- National Health and Medical Research Council (1016701, 1016647, 1020363, 1145728)
- Deutsche Krebshilfe
This publication has 63 references indexed in Scilit:
- BH3 profiling – Measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisionsCancer Letters, 2013
- Structure-guided design of a selective BCL-XL inhibitorNature Chemical Biology, 2013
- Inflammation and Immunity in Radiation Damage to the Gut MucosaBioMed Research International, 2013
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- Chronic Kidney Disease After Hematopoietic Stem Cell TransplantationSeminars in Nephrology, 2010
- Mitochondria and cell death: outer membrane permeabilization and beyondNature Reviews Molecular Cell Biology, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- The Hallmarks of CancerCell, 2000